Navigation Links
Discovery yields master regulator of toxin production in staph infections
Date:8/6/2014

St. Jude Children's Research Hospital scientists have discovered an enzyme that regulates production of the toxins that contribute to potentially life-threatening Staphylococcus aureus infections. The study recently appeared in the scientific journal the Proceedings of the National Academy of Sciences (PNAS).

Researchers also showed that the same enzyme allows Staphylococcus aureus to use fatty acids acquired from the infected individual to make the membrane that bacteria need to grow and flourish. The results provide a promising focus for efforts to develop a much-needed new class of antibiotics to combat staph and other Gram-positive infections. Staphylococcus aureus is the most common cause of staph infections, including methicillin-resistant Staphylococcus aureus (MRSA), the drug-resistant infection that is a growing problem in hospitals.

"Staphylococcus aureus is a clear and present danger to patients worldwide," said corresponding author Charles Rock, Ph.D., a member of the St. Jude Department of Infectious Diseases. "We set out to answer a long-standing question about bacterial membrane biochemistry and discovered a master regulator of the virulence factors that make staph infections so destructive and dangerous. The pathway we identified offers an exciting new target for antibiotic drug development."

Virulence factors include dozens of proteins that bacteria make and secrete. The factors cause many symptoms and infection-related problems, including destruction of cells and tissue, and evasion of the immune system.

The enzyme Rock and his colleagues discovered is fatty acid kinase (FAK). Researchers showed that FAK is formed by the proteins FakA and FakB1 or FakB2. Scientists demonstrated how FakA and FakB work together to replace fatty acids in the bacterial membrane with fatty acids from the person infected.

Fatty acids are a key component of the phospholipids that make up a significant part of the bacterial membrane. Bacteria produce their own fatty acids, but some, including Staphylococcus aureus, can also borrow from their host, which reduces the demands on bacteria to make their own. Until now, however, the enzyme used to incorporate host fatty acids was unknown.

Researchers showed that different genes carry instructions for making the FAK proteins. Loss of the genes disrupted the ability of bacteria to incorporate host fatty acids into the bacterial membrane. "The big surprise was that loss of these genes also impacted production of virulence factors," Rock said. "The mutant Staphylococcus aureus did not make the proteins responsible for many of the symptoms caused by these infections."

Earlier research from Rock hinted at a connection between fatty acid synthesis and production of virulence factors, but this study is the first to establish the biochemical link and identify the mechanism involved. Evidence suggests that FAK functions in the transcriptional regulation of virulence factor production, switching on genes that carry instructions for making the proteins. "In fact, FAK's primary role in bacteria might be as a transcriptional regulator," Rock said.

Researchers also detailed how FAK handles its duties related to membrane phospholipids. FakA includes the kinase domain, which allows the protein to function as an enzyme. FakB1 binds saturated fatty acids while FakB2 prefers unsaturated fatty acids.

When FakA interacts with either FakB1 or FakB2 a phosphate is transferred onto the FakB fatty acid, producing acyl-phosphate, a chemical intermediate not found in humans. The acyl-phosphate is used as a substitute for fatty acids normally made by the bacteria.

The paper's first author is Josh Parsons, Ph.D., a postdoctoral fellow in Rock's laboratory. The other authors are Tyler Broussard, Jason Rosch, Pamela Jackson and Chitra Subramanian, all of St. Jude; and Jeffrey Bose, of the University of Kansas, Kansas City.

The study was supported in part by a grant (GM034496) from the National Institutes of Health (NIH), a grant (CA21765) from the National Cancer Institute at the NIH and ALSAC.


'/>"/>
Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Washingtons Life Sciences Discovery Fund awards commercialization grants
3. Discovery could help to develop drugs for organ transplant and cancer patients
4. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
5. H1N1 discovery paves way for universal flu vaccine: UBC research
6. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
7. Researchers make promising discovery in pursuit of effective lymphoma treatments
8. Discovery suggests new combination therapy strategy for basal-like breast cancers
9. Discovery of Gene May Lead to New Male Contraceptive
10. 5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
11. Illnesses in Colorado childrens hospital prompts discovery of contaminated alcohol pads
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be a result ... has helped many women become pregnant upon treating their diagnosis. , ... outpatient evaluations. We can provide the necessary information to diagnose and treat ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... expertise for sponsors and CROs to speed clinical development, has released the ... platform. Bioclinica AGILE RTSM provides seamless clinical supply forecasting and ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates ... Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition Duchenne ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new patients ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients can ... more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from medical ... heartened by the industry’s current surge. But another thing that unifies them is a ... last they can simply, safely and effectively end their aroma anguish thanks to a ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/18/2017)...  Cardinal Health (NYSE: CAH ) today ... per share (EPS) guidance and providing a preliminary view ... with this morning,s announcement of the planned acquisition of ... businesses. Cardinal Health now believes that fiscal ... the bottom of its previous guidance range of $5.35 ...
Breaking Medicine Technology: